GLP-1 patent portfolios typically split across: Molecule (composition) patents : sequences, modifications, and variants that define the active pharmaceutical ingredient
GLP-1R biased cAMP agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian models Glucagon-like peptide-1 receptor (GLP-1R) agonists improve glycemic control and promote weight loss in diabetes and obesity but are also associated with gastrointestinal adverse events, including nausea and emesis in many patients
Effects of GSH on Alcohol Metabolism and Hangover Improvement in Humans: A Randomised Double-Blind Placebo-Controlled Crossover Clinical Trial [online]
Swelling of the face, lips, tongue, or throat
With Phase 3 trials now actively enrolling, the medical community must track this development closely
Across GLP-1 trials, roughly 60% of lost weight returns within a year and about 75% over the longer regain curve. Lower-dose maintenance has stronger evidence than complete withdrawal